SBIR/STTR Research Award

Advanced portable low temperature plasma device for chronic wound disinfection and healing

Award identifier cb9a77995e878926da66dce933256f42a3e8121c04e0c5006df4b51a0a5ba22aAwarding agency Department of Energy

Award amount

$200,000

Program and phase

SBIR · Phase I

Award year

2023

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Energy
Branch
Not reported
Recipient company
ZYMERON CORPORATION
Proposal award date
2023-07-10
Contract end date
2024-04-09
UEI
GAMMMRQ6QMN1
Solicitation number
DE-FOA-0002903
Topic code
C56-31a

Research abstract

Management of chronic wounds remains a clinical challenge, especially when the wounds are infected by either biofilms or antibiotic-resistant microbial pathogens. Low temperature plasma (LTP) technique has demonstrated its proof of concept as an effective, non-antibiotic approach for wound disinfection. So far, commercial medical LTP devices leverage the direct exposure of plasma plume to the wound tissue, which leads to an increased risk of irreversible tissue damage. Besides the safety concerns, high manufacturing expenses and low portability among many other disadvantages prevent the widespread clinical translations of the LTP technology. Zymeron proposes to develop ZymPlasTM, a convenient, portable, and highly effective low temperature plasma device for chronic wound disinfection and healing at the point of care. ZymPlas adopts innovative plasma chemistry, which allows effective wound disinfection without the direct exposure of wound tissue to plasma plume. Besides, the novel plasma generation system and the compact design allow cost-effective manufacturing and improved portability. In the Phase I period, Zymeron will design and construct a functioning ZymPlasTM prototype device and optimize the relevant plasma chemistry. Next, the wound disinfection efficacy of the prototype device will be evaluated in ex vivo wound biofilm models using both Gram-negative and Gram-positive strains. Finally, the prototype device will be tested in a well-established mouse chronic wound infection model to validate the efficacy of wound disinfection and healing. ZymPlas can address wound infection and biofilm issues and thus brings significant clinical benefits (e.g., decreasing the wound chronicity, restoring impaired healing, reducing regular care frequency, shortening wound closure time) and reduces the financial and medical burden. Moreover, ZymPlas is also ideal for other applications such as acute trauma treatment, burn treatment, and surgical disinfection. The portable device design, simple operation procedure, and disinfection efficiency could match numerous applications in wound healing and dermatology therapeutic areas.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

42 SBIR/STTR records share this UEI (2017–2024). Reported award amounts total $24,710,238. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Defense, Department of Health and Human Services, Department of Energy

Agency intelligence

Department of Energy

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.